BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 33870423)

  • 1. FOXP4-AS1 is a favorable prognostic-related enhancer RNA in ovarian cancer.
    Hua T; Tian YJ; Wang RM; Zhao CF; Kong YH; Tian RQ; Wang W; Ma LX
    Biosci Rep; 2021 Apr; 41(4):. PubMed ID: 33870423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identify potential clinical significance of long noncoding RNA forkhead box P4 antisense RNA 1 in patients with early stage pancreatic ductal adenocarcinoma.
    Liu XG; Xu H; Chen M; Tan XY; Chen XF; Yang YG; Lin MZ; Liu GH; Liang XL; Qian YB; Yuan GJ; Chen MQ; Li WT; Miao HL; Li MY; Liao XW; Dai W; Chen NP
    Cancer Med; 2020 Mar; 9(6):2062-2076. PubMed ID: 31991068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long non-coding RNA FOXP4-AS1 is a prognostic biomarker and associated with immune infiltrates in ovarian serous cystadenocarcinoma.
    Liao C; Wang A; Ma Y; Liu H
    Medicine (Baltimore); 2021 Oct; 100(40):e27473. PubMed ID: 34622876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical prognostic value of lncRNA FOXP4-AS1 in cancer patients: A meta-analysis and bioinformatics analysis based on TCGA datasets.
    Shu Q; Liu X; Yang J; Mou T; Xie F
    Medicine (Baltimore); 2022 Oct; 101(42):e31439. PubMed ID: 36281152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Integrative Analysis Revealing ZFHX4-AS1 as a Novel Prognostic Biomarker Correlated with Immune Infiltrates in Ovarian Cancer.
    Huang C; Cui H; Lang X; Zhao F
    J Immunol Res; 2022; 2022():9912732. PubMed ID: 35795530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TBX5-AS1, an enhancer RNA, is a potential novel prognostic biomarker for lung adenocarcinoma.
    Cheng L; Han T; Chen B; Nie K; Peng W
    BMC Cancer; 2021 Jul; 21(1):794. PubMed ID: 34238250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LncRNA FOXP4-AS1 is activated by PAX5 and promotes the growth of prostate cancer by sequestering miR-3184-5p to upregulate FOXP4.
    Wu X; Xiao Y; Zhou Y; Zhou Z; Yan W
    Cell Death Dis; 2019 Jun; 10(7):472. PubMed ID: 31209207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long non-coding RNA FOXP4-AS1 is an unfavourable prognostic factor and regulates proliferation and apoptosis in colorectal cancer.
    Li J; Lian Y; Yan C; Cai Z; Ding J; Ma Z; Peng P; Wang K
    Cell Prolif; 2017 Feb; 50(1):. PubMed ID: 27790757
    [TBL] [Abstract][Full Text] [Related]  

  • 9. YY1-induced upregulation of FOXP4-AS1 and FOXP4 promote the proliferation of esophageal squamous cell carcinoma cells.
    Li Y; Li T; Yang Y; Kang W; Dong S; Cheng S
    Cell Biol Int; 2020 Jul; 44(7):1447-1457. PubMed ID: 32159250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EMX2OS plays a prognosis-associated enhancer RNA role in gastric cancer.
    Liu GX; Tan YZ; He GC; Zhang QL; Liu P
    Medicine (Baltimore); 2021 Oct; 100(41):e27535. PubMed ID: 34731149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FOXP4-mediated induction of PTK7 activates the Wnt/β-catenin pathway and promotes ovarian cancer development.
    Ji J; Qian Q; Cheng W; Ye X; Jing A; Ma S; Ding Y; Ma X; Wang Y; Sun Q; Wang X; Chen Y; Zhu L; Yuan Q; Xu M; Qin J; Ma L; Yang J; Zhang M; Geng T; Wang S; Wang D; Song Y; Zhang B; Xu Y; Xu L; Liu S; Liu W; Liu B
    Cell Death Dis; 2024 May; 15(5):332. PubMed ID: 38740744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long non-coding RNA FOXP4-AS1 acts as an adverse prognostic factor and regulates proliferation and apoptosis in nasopharyngeal carcinoma.
    Zhong LK; Zhou J; He X; He BF; Zhou XW; Zhu JL; Liu J; Qiu YH
    Eur Rev Med Pharmacol Sci; 2020 Aug; 24(15):8008-8016. PubMed ID: 32767327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive Analysis of Enhancer RNAs Identifies LINC00689 and ELFN1-AS1 as Novel Prognostic Biomarkers in Uveal Melanoma.
    Zhao S; Jiang H; Liu J; Li DY; Li B; Long QR; Zheng L; Gu H
    Dis Markers; 2022; 2022():5994800. PubMed ID: 35251374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Participation of Long Noncoding RNA
    Liu L; Zhao J; Guo H; Jia J; Shi L; Ma J; Zhang Z
    Cancer Biother Radiopharm; 2024 Mar; ():. PubMed ID: 38512300
    [No Abstract]   [Full Text] [Related]  

  • 15. LINC00887 Acts as an Enhancer RNA to Promote Medullary Thyroid Carcinoma Progression by Binding with FOXQ1.
    Liu D; Wang W; Wu Y; Qiu Y; Zhang L
    Curr Cancer Drug Targets; 2024; 24(5):519-533. PubMed ID: 38804344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased expression of long noncoding RNA HMMR-AS1 in epithelial ovarian cancer: an independent prognostic factor.
    Chu ZP; Dai J; Jia LG; Li J; Zhang Y; Zhang ZY; Yan P
    Eur Rev Med Pharmacol Sci; 2018 Dec; 22(23):8145-8150. PubMed ID: 30556852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FOXP4-AS1 participates in the development and progression of osteosarcoma by downregulating LATS1 via binding to LSD1 and EZH2.
    Yang L; Ge D; Chen X; Qiu J; Yin Z; Zheng S; Jiang C
    Biochem Biophys Res Commun; 2018 Aug; 502(4):493-500. PubMed ID: 29859193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FOXP4-AS1 May be a Potential Prognostic Biomarker in Human Cancers: A Meta-Analysis and Bioinformatics Analysis.
    Zhang G; Wang Y; Han X; Lu T; Fu L; Jin H; Yang K; Cai H
    Front Oncol; 2022; 12():799265. PubMed ID: 35719909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression levels and associations of five long non-coding RNAs in gastric cancer and their clinical significance.
    Binang HB; Wang YS; Tewara MA; Du L; Shi S; Li N; Nsenga AGA; Wang C
    Oncol Lett; 2020 Mar; 19(3):2431-2445. PubMed ID: 32194743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Downregulated Long Noncoding RNA GAS5 Fails to Function as Decoy of CEBPB, Resulting in Increased GDF15 Expression and Rapid Ovarian Cancer Cell Proliferation.
    Guo LL; Wang SF
    Cancer Biother Radiopharm; 2019 Oct; 34(8):537-546. PubMed ID: 31314588
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.